Baseline clinical and demographic characteristics of patients with myelofibrosis
| Characteristic . | All patients (n = 100) . | PMF (n = 50) . | PPV-MF (n = 27) . | PET-MF (n = 23) . |
|---|---|---|---|---|
| Age, median (range), y | 68 (43-86) | 66 (43-86) | 68 (54-80) | 70 (48-82) |
| Male, n (%) | 62 (62) | 32 (64) | 18 (67) | 12 (52) |
| Hb concentration, median (range), g/L | 98 (64-158) | 103 (73-158) | 106 (64-148) | 96 (72-121) |
| WCC, median (range), ×109/L | 14.6 (1.6-109.4) | 11.7 (1.6-65) | 19.8 (3.1-109.4) | 14.4 (2.2-50.5) |
| Plt count, median (range), ×109/L | 199 (17-1345) | 225 (17-1072) | 168 (46-647) | 237 (45-1345) |
| PBB ≥1%, n (%) | 56 (56) | 28 (56) | 13 (48) | 15 (65) |
| Baseline palpable spleen size, median (range), cm | 17 (0-38) | 17 (0-38) | 16 (8-32) | 18 (5-31) |
| Transfusion dependence prior to starting JAK inhibitor, n (%) | 39 (39) | 18 (36) | 11 (41) | 10 (43) |
| ECOG scale score, n (%) | ||||
| 0 | 20 (20) | 11 (22) | 6 (22) | 3 (13) |
| 1 | 68 (68) | 34 (68) | 16 (59) | 18 (78) |
| 2 | 10 (10) | 5 (10) | 4 (15) | 1 (4) |
| Missing | 2 (2) | 0 (0) | 1 (4) | 1 (4) |
| DIPSS score, n (%) | ||||
| Low | 1 (1) | 1 (2) | 0 (0) | 0 (0) |
| Intermediate-1 | 27 (27) | 17 (34) | 7 (26) | 3 (13) |
| Intermediate-2 | 43 (43) | 22 (44) | 9 (33) | 12 (52) |
| High | 29 (29) | 10 (20) | 11 (41) | 8 (35) |
| Cytogenetics, n (%) | ||||
| Normal | 47 (47) | 23 (46) | 11 (41) | 13 (57) |
| Abnormal, favorable | 23 (23) | 12 (24) | 7 (26) | 4 (17) |
| Abnormal, not favorable | 5 (5) | 3 (6) | 0 (0) | 2 (9) |
| Failed/not done | 25 (25) | 12 (24) | 9 (33) | 4 (17) |
| JAK inhibitor, n (%) | ||||
| Ruxolitinib | 77 (77) | 35 (70) | 25 (93) | 17 (74) |
| Momelotinib | 23 (23) | 15 (30) | 2 (7) | 6 (26) |
| Received as part of clinical trial, n (%) | 47 (47) | 24 (48) | 12 (44) | 11 (48) |
| Characteristic . | All patients (n = 100) . | PMF (n = 50) . | PPV-MF (n = 27) . | PET-MF (n = 23) . |
|---|---|---|---|---|
| Age, median (range), y | 68 (43-86) | 66 (43-86) | 68 (54-80) | 70 (48-82) |
| Male, n (%) | 62 (62) | 32 (64) | 18 (67) | 12 (52) |
| Hb concentration, median (range), g/L | 98 (64-158) | 103 (73-158) | 106 (64-148) | 96 (72-121) |
| WCC, median (range), ×109/L | 14.6 (1.6-109.4) | 11.7 (1.6-65) | 19.8 (3.1-109.4) | 14.4 (2.2-50.5) |
| Plt count, median (range), ×109/L | 199 (17-1345) | 225 (17-1072) | 168 (46-647) | 237 (45-1345) |
| PBB ≥1%, n (%) | 56 (56) | 28 (56) | 13 (48) | 15 (65) |
| Baseline palpable spleen size, median (range), cm | 17 (0-38) | 17 (0-38) | 16 (8-32) | 18 (5-31) |
| Transfusion dependence prior to starting JAK inhibitor, n (%) | 39 (39) | 18 (36) | 11 (41) | 10 (43) |
| ECOG scale score, n (%) | ||||
| 0 | 20 (20) | 11 (22) | 6 (22) | 3 (13) |
| 1 | 68 (68) | 34 (68) | 16 (59) | 18 (78) |
| 2 | 10 (10) | 5 (10) | 4 (15) | 1 (4) |
| Missing | 2 (2) | 0 (0) | 1 (4) | 1 (4) |
| DIPSS score, n (%) | ||||
| Low | 1 (1) | 1 (2) | 0 (0) | 0 (0) |
| Intermediate-1 | 27 (27) | 17 (34) | 7 (26) | 3 (13) |
| Intermediate-2 | 43 (43) | 22 (44) | 9 (33) | 12 (52) |
| High | 29 (29) | 10 (20) | 11 (41) | 8 (35) |
| Cytogenetics, n (%) | ||||
| Normal | 47 (47) | 23 (46) | 11 (41) | 13 (57) |
| Abnormal, favorable | 23 (23) | 12 (24) | 7 (26) | 4 (17) |
| Abnormal, not favorable | 5 (5) | 3 (6) | 0 (0) | 2 (9) |
| Failed/not done | 25 (25) | 12 (24) | 9 (33) | 4 (17) |
| JAK inhibitor, n (%) | ||||
| Ruxolitinib | 77 (77) | 35 (70) | 25 (93) | 17 (74) |
| Momelotinib | 23 (23) | 15 (30) | 2 (7) | 6 (26) |
| Received as part of clinical trial, n (%) | 47 (47) | 24 (48) | 12 (44) | 11 (48) |
No P value was found to be statistically significant between MF subtypes.
ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; PBB, peripheral blood blast; Plt, platelet; WCC, white blood cell count.